- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study from NCPA sheds new light on med synchronization programs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
HYDERABAD, India — Indian generic drug maker Aurobindo has received two approvals from the Food and Drug Administration.
The company said Wednesday that it received approval for galantamine tablets in the 4-, 8- and 12-mg strengths. The drug is a version of Johnson & Johnson’s Alzheimer’s treatment Razadyne; various versions of the drug had sales of $41 million during the 12 months ended in September 2010, according to IMS Health.
On Thursday, the FDA approved Aurobindo’s fosinopril sodium tablets in the 10-, 20- and 40-mg strengths. The drug is a generic version of Bristol-Myers Squibb’s Monopril and is used to treat hypertension. Versions of the drug had sales of $20 million during the 12-month period ended in September 2010, according to IMS.